Literature DB >> 15538042

Expression of FGF-2 alters focal adhesion dynamics in migration-restricted MDA-MB-231 breast cancer cells.

Reju Korah1, Lydia Choi, Judith Barrios, Robert Wieder.   

Abstract

Basic fibroblast growth factor (FGF-2) expression takes place during morphogenic differentiation of mammary ducts and is lost in breast cancer. Forced re-expression of FGF-2 in breast cancer cell lines induces a more differentiated phenotype and inhibits motility by unknown mechanisms. Here we demonstrate that MDA-MB-231 cells with encumbered motility due to forced re-expression of FGF-2 have activated focal complexes as determined by immunoprecipitation/western blotting and immunofluorescence staining with antibodies to FAK, p130Cas, paxillin, vinculin and phosphotyrosine. The activation of the focal adhesion complexes results in loss of stress fibers associated with malignant transformation of mammary epithelial cells and the formation of circumferentially-distributed actin bundles associated with non-transformed mammary epithelial cells. These effects require continuous FGF-2 expression, as the effects of exogenous recombinant FGF-2 are only small and transient. FGF-2 expression results in an increase in integrin alpha 3 expression and decreases in integrin beta 1 and beta 4 expression. These changes, however, induce only a small decrease in adhesion to uncoated and fibronectin-coated tissue culture dishes suggesting that the primary cause of impaired motility is due to intrinsic signaling. These data suggest that FGF-2-inhibits motility in breast cancer cells by stabilization of focal complexes and induction of a more differentiated phenotype with disruption of stress fiber formation and a characteristic cortical actin distribution.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15538042     DOI: 10.1007/s10459-004-6006-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  14 in total

1.  Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth.

Authors:  Christine F O'Neill; Sumithra Urs; Christina Cinelli; Alexis Lincoln; Robert J Nadeau; Ruth León; Jessica Toher; Carla Mouta-Bellum; Robert E Friesel; Lucy Liaw
Journal:  Am J Pathol       Date:  2007-08-03       Impact factor: 4.307

2.  Breast cancer at bone metastatic sites: recent discoveries and treatment targets.

Authors:  Osama Hussein; Svetlana V Komarova
Journal:  J Cell Commun Signal       Date:  2011-01-19       Impact factor: 5.782

Review 3.  Progress in researches about focal adhesion kinase in gastrointestinal tract.

Authors:  Hui-Fang Hao; Yoshio Naomoto; Xiao-Hong Bao; Nobuyuki Watanabe; Kazufumi Sakurama; Kazuhiro Noma; Yasuko Tomono; Takuya Fukazawa; Yasuhiro Shirakawa; Tomoki Yamatsuji; Junji Matsuoka; Munenori Takaoka
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

Review 4.  CAS proteins in normal and pathological cell growth control.

Authors:  Nadezhda Tikhmyanova; Joy L Little; Erica A Golemis
Journal:  Cell Mol Life Sci       Date:  2009-11-25       Impact factor: 9.261

5.  Transforming growth factor-beta stimulates intestinal epithelial focal adhesion kinase synthesis via Smad- and p38-dependent mechanisms.

Authors:  Mary F Walsh; Dinakar R Ampasala; James Hatfield; Richard Vander Heide; Silke Suer; Arun K Rishi; Marc D Basson
Journal:  Am J Pathol       Date:  2008-06-26       Impact factor: 4.307

Review 6.  Cancer micrometastases.

Authors:  Klaus Pantel; Catherine Alix-Panabières; Sabine Riethdorf
Journal:  Nat Rev Clin Oncol       Date:  2009-06       Impact factor: 66.675

Review 7.  The role of fibroblast growth factors in tumor growth.

Authors:  M Korc; R E Friesel
Journal:  Curr Cancer Drug Targets       Date:  2009-08-01       Impact factor: 3.428

8.  A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents.

Authors:  Ly Tu; Frances S De Man; Barbara Girerd; Alice Huertas; Marie-Camille Chaumais; Florence Lecerf; Charlène François; Frédéric Perros; Peter Dorfmüller; Elie Fadel; David Montani; Saadia Eddahibi; Marc Humbert; Christophe Guignabert
Journal:  Am J Respir Crit Care Med       Date:  2012-07-12       Impact factor: 21.405

9.  Dual FGF-2 and intergrin alpha5beta1 signaling mediate GRAF-induced RhoA inactivation in a model of breast cancer dormancy.

Authors:  Judith Barrios; Robert Wieder
Journal:  Cancer Microenviron       Date:  2009-03-18

10.  Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma.

Authors:  Reju Korah; James M Healy; John W Kunstman; Annabelle L Fonseca; Amir H Ameri; Manju L Prasad; Tobias Carling
Journal:  Mol Cancer       Date:  2013-08-05       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.